News
- 2024/06/21 Orphan drug designated D07001 heading to global phase 3 pivotal study
- 2024/01/18 Innopharmax's product Innomustine® has been approved for benefit coverage by National Health Insurance (NHI), and can be used in
- 2022/08/29 InnoPharmax have signed supplementary agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride.
- 2022/03/29 Patent of “Oral Administration of Unstable or Poorly-Absorbed Drugs (N11005)” was granted in U.S.
- 2022/02/10 First-Patient-In (FPI) of N11005-Oral Insulin Investigator-Initiated-Trial (IIT).
Vision and Strategy
Technologies
R&D
